Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808534 · ClinicalTrials.gov registry record · Phase 2
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01808534: Clinical Trial Phase 2 study, sponsored by Indiana University.
NCT01808534 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01808534, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Primary Outcome
The percent of patients who were shown as having a partial remission or better based on definitions of response in RECIST 1.1. At least a 30% decrease in the sum of the diameters of target lesions, in reference to baseline sum diameters, needs to be confirmed to be considered as partial response or better. Note: There were no patients with a partial or complete response.
Interventions
- DRUG palifosfamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Why NCT01808534 stopped before completion
NCT01808534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which palifosfamide is the first listed.
NCT01808534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01808534 about?
NCT01808534 is a clinical study titled "Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors". This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
What is the current status of trial NCT01808534?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01808534?
The interventions under investigation include: palifosfamide (DRUG).
Who is sponsoring clinical trial NCT01808534?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01808534's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia